| Placebo | rm-APC | placebo | rm-APC |
---|---|---|---|---|
MPO (ng/ml) | 5.0 (3.9 to 5.9) | 4.9 (4.2 to 5.1) | 6.4 (5.6 to 6.9) | 6.8 (6.2 to 8.9) |
TNF-α (pg/ml) | 120 (97 to 134) | 121 (101 to 143) | 393 (293 to 495) | 167 (139 to 344) * |
IL-1β (pg/ml) | 236 (100 to 415) | 389 (331 to 389) | 479 (444 to 549) | 371 (345 to 587) |
IL-6 (ng/ml) | 0.9 (0.7 to 1.0) | 0.8 (0.7 to 0.9) | 1.3 (1.0 to 1.6) | 1.0 (0.7 to 1.3) |
IL-12 (pg/ml) | B.D. | B.D. | 54 (37 to 64) | 11 (5.0 to 28) * |
IL-10 (pg/ml) | 137 (86 to 165) | 131 (101 to 153) | 115 (82 to 175) | 65 (23 to 147) |
IFN-γ (pg/ml) | 6.8 (6.0 to 9.7) | 6.9 (5.8 to 7.9) | 6.7 (4.9 to 8.1) | 5.6 (3.5 to 7.9) |
KC (ng/ml) | 3.1 (2.3 to 3.7) | 4.0 (2.9 to 5.1) | 3.4 (2.6 to 4.4) | 4.2 (3.3 to 5.6) |
MIP-2 (ng/ml) | 1.2 (0.8 to 1.4) | 1.5 (1.2 to 1.6) | 1.4 (1.3 to 1.5) | 1.5 (1.4 to 1.7) |